LOGUE, OMAR C;
EDDY, ADRIAN C;
MOORE, KYLE;
CHAPMAN, HEATHER;
GEORGE, ERIC M;
Bidwell, Gene L
Abstract P3045: The ELP-VEGF Fusion Protein Is Bioavailable After Subcutaneous Administration And Prevents Increased Blood Pressure In Response To Placental Ischemia
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Abstract P3045: The ELP-VEGF Fusion Protein Is Bioavailable After Subcutaneous Administration And Prevents Increased Blood Pressure In Response To Placental Ischemia
Contributor:
LOGUE, OMAR C;
EDDY, ADRIAN C;
MOORE, KYLE;
CHAPMAN, HEATHER;
GEORGE, ERIC M;
Bidwell, Gene L
Description:
<jats:p>
Preeclampsia is often characterized by high circulating levels of sFlt-1 and low VEGF and PlGF. VEGF supplementation therapy has shown promise in preclinical models, however rapid plasma clearance hampers the use of VEGF as a therapeutic. We fused human VEGF-A
<jats:sub>121</jats:sub>
with the Elastin-like Polypeptide (ELP) protein carrier. The objective of this study was to test the pharmacokinetics and therapeutic efficacy of ELP-VEGF when given via intravenous (IV) and subcutaneous (SC) administration routes.Fluorescently labeled ELP-VEGF was administered via daily IV (5 mg/kg/day) or SC injection (50 mg/kg/day). Plasma levels were determined by direct fluorescence measurement, and whole-body fluorescence imaging was used to determine total tissue clearance rates. The ability of SC delivered ELP-VEGF to modulate blood pressure was tested in a rat model of placental ischemia.When administered via IV injection, ELP-VEGF cleared from the plasma with an average daily half-life of 2.17±1.14 h. SC injected ELP-VEGF was absorbed into the blood and peaked within 2 hours of each injection. Tissue levels peaked 2h after each injection and remained elevated prior to the next injection, resulting in accumulation and high whole-body bioavailability. In pregnant rats, placental ischemia induced an increase in mean arterial pressure (108 ±11 vs. 122±13 mmHg, p=0.024). Daily SC injection of ELP-VEGF (50 mg/kg/day) completely prevented placental ischemia-induced increases in blood pressure (107±11 vs. 109±9 mmHg, p=ns). These results demonstrate that ELP-VEGF is bioavailable via clinically relevant administration routes and is a promising candidate agent for preeclampsia therapy.
</jats:p>
<jats:p>
<jats:graphic xmlns:xlink="http://www.w3.org/1999/xlink" orientation="portrait" position="float" xlink:href="g853.jpg" />
</jats:p>